The ProLung Technology

ProLung provides the only lung cancer risk stratification approach specific to the chest. The technology uses mass-averaging bioconductance to exploit the differences in conductance between malignant and benign tissue.

The EPN Scan System guides the technician to take measurements at 62 pathways through the chest from anatomical landmarks on the chest, hands, and upper back. The bioconductance measurements are then analyzed by a classifier algorithm which differentiates between increased and decreased risk of lung cancer.

The physician report provides a fast and easy to interpret composite score.


The ProLung Clinical Approach


A CT scan identifies a pulmonary nodule suspicious for cancer

Every year, CT scans reveal a lung spot or mass in 15 million people worldwide. A CT scan cannot determine whether the mass is malignant (i.e. cancerous) or benign. Because there is not an immediate and non-invasive way to identify malignancy in the lungs, repeated CT scans are prescribed up to six times for up to 3½ years to detect growth in the mass, an indication of cancer. By the time this growth is detected, the cancer has often progressed to the point that treatment is ineffective.

Physician orders the ProLung Test to evaluate the risk of lung cancer

Instead of relying on repeated CT scans, The ProLung Test™ uses an established bioconductance technology – similar to an EEG or EKG – to risk stratify patients who are likely to have lung lesions suspicious for cancer. The patented computerized EPN Scan System™ can be used in conjunction with Low-Dose CT screening to evaluate masses identified by these scans for high or low risk of malignancy.

Physician reviews test results and other risk factors to determine a course of action

The EPN Scan captures thousands of precise measurements and produces a risk stratification composite score that provides the physician, surgeon, and patient with additional information in determining the risk of a suspicious lung mass being malignant.